Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan and Bevacizumab with Re-radiotherapy for Recurrent Glioblastoma
NCT05201326Phase 1Unknown
- Sponsor
- Ruijin Hospital
- Start
- Dec 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bevacizumab and irinotecan in glioblastoma (GBM), sponsored by Ruijin Hospital. Primary endpoint: Serious Adverse Events. Status: unknown.
02
Drugs
bevacizumabirinotecan
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05201326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05201326.